Form 8-K - Current report:
SEC Accession No. 0001193125-20-309615
Filing Date
2020-12-03
Accepted
2020-12-03 16:54:54
Documents
13
Period of Report
2020-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d73841d8k.htm   iXBRL 8-K 41234
2 EX-4.1 d73841dex41.htm EX-4.1 959418
  Complete submission text file 0001193125-20-309615.txt   1319118

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bhc-20201203.xsd EX-101.SCH 2733
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bhc-20201203_lab.xml EX-101.LAB 18081
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bhc-20201203_pre.xml EX-101.PRE 11272
6 EXTRACTED XBRL INSTANCE DOCUMENT d73841d8k_htm.xml XML 3555
Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8
Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792
Bausch Health Companies Inc. (Filer) CIK: 0000885590 (see all company filings)

EIN.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14956 | Film No.: 201367493
SIC: 2834 Pharmaceutical Preparations